In sarcomatoid cHCC-ICC, mutations in the TP53 and pTERT genes were recently described, along with PDL-1 expression, as indicators of possible targeted therapy with immune checkpoint inhibitors (ICPIs) (Yoshuantari et al. 2023; Zheng et al. 2020). This evidence concerns the gene TP53 and intrahepatic cholangiocarcinoma.